Phase 1 Study of VT-101 in Advanced Ovarian Cancer
A Phase 1 Dose-Finding, Safety, and Preliminary Clinical Activity Study of VT-101 in Advanced Ovarian Cancer
This Phase 1, open-label study will evaluate VT-101, an investigational small-molecule therapy, in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer. The primary objectives are to assess the safety, tolerability, and pharmacokinetic profile of VT-101 and to identify a recommended dose for further study. Secondary and exploratory objectives include evaluation of preliminary antitumor activity and characterization of treatment-related effects in participants with limited standard treatment options.
調査の概要
詳細な説明
This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer. Eligible participants must have disease that has progressed following prior therapy or have exhausted, refused, become intolerant of, or are otherwise ineligible for available standard treatment options.
Participants will receive VT-101 administered according to a dose-escalation design to evaluate the safety profile of escalating dose levels and to identify an appropriate dose and schedule for further clinical development. Safety assessments will include the evaluation of adverse events, serious adverse events, dose-limiting toxicities, clinical laboratory parameters, physical examinations, vital signs, and other protocol-specified assessments.
Pharmacokinetic analyses will be performed to characterize the absorption, distribution, metabolism, and elimination of VT-101. Antitumor activity will be assessed using protocol-defined efficacy endpoints, including tumor response and disease control measures. Exploratory analyses may evaluate biomarkers and other factors associated with treatment response and clinical outcomes.
The information generated from this study will support determination of the safety profile, pharmacokinetic characteristics, and recommended dose of VT-101 for subsequent clinical investigation in patients with advanced epithelial ovarian cancer.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前：Michael Goodheart, MD
- 電話番号：+1 319 356 2015
- メール：michael-goodheart@uiowa.edu
研究場所
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- 募集
- University of Iowa Health Care
-
コンタクト：
- Michael Goodheart, MD
- メール：michael-goodheart@uiowa.edu
-
コンタクト：
- Kerri Fitch
- 電話番号：(319) 467-5838
- メール：kerri-fitch@uiowa.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
ELIGIBILITY CRITERIA
Inclusion Criteria:
- Female participant
- Age ≥ 18 years
- Histologically confirmed advanced, recurrent, or relapsed epithelial ovarian cancer
- Has received prior standard therapy for ovarian cancer, OR has refused standard therapy, OR is intolerant to standard therapy, OR is not eligible for standard therapy
- ECOG Performance Status of 0, 1, or 2
- Adequate bone marrow, liver, and kidney function as defined by the protocol
- Able to comply with study procedures and provide informed consent
- For women of childbearing potential: agrees to use protocol-required contraception and meets pregnancy testing requirements
Exclusion Criteria (high-level):
- Does not meet the inclusion criteria
- Medical conditions or laboratory abnormalities that would make study participation unsafe
- Other protocol-defined exclusions as determined by the investigator
Sex:
• Female only
Age:
- 18 years and older
- No upper age limit specified
Healthy Volunteers:
- No
- Healthy volunteers are not eligible
- Participants must have advanced, recurrent, or relapsed epithelial ovarian cancer
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：VT-101 Dose Escalation and Expansion
Participants will receive VT-101 by intraperitoneal administration once weekly for four doses on Days 1, 8, 15, and 22. During Phase I, doses will be escalated using a standard 3+3 design, starting at 1 × 10⁸ microvesicles (MVs) per dose, followed by 1 × 10⁹ and 1 × 10¹⁰ MVs per dose. Once the maximum tolerated dose (MTD) is determined, enrollment at the MTD will be expanded to include 10 patients in the efficacy evaluation. Patients treated at the MTD during Phase I will count toward this total. |
VT-101 is an investigational therapy consisting of autologous M1 macrophage-derived vesicles generated through membrane fragmentation. VT-101 is administered intraperitoneally via an implanted port over approximately 45 minutes, once weekly on Days 1, 8, 15, and 22, for four doses. Phase I dose escalation follows a standard 3+3 design, beginning at 1 × 10⁸ vesicles per dose and escalating to 1 × 10⁹ and 1 × 10¹⁰ vesicles per dose. Each participant receives the same dose level. After the maximum tolerated dose is established, an expansion cohort will evaluate preliminary efficacy at that dose. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Dose-Limiting Toxicities (DLTs)
時間枠：From the first dose through 14 days after the Day 22 dose. This reflects the Phase I primary endpoint and the protocol's specified toxicity-monitoring window.
|
Number of participants experiencing dose-limiting toxicities (DLTs) during Phase I dose escalation. The maximum tolerated dose (MTD) will be defined as the highest dose level at which no more than 1 of 6 participants experiences a DLT. |
From the first dose through 14 days after the Day 22 dose. This reflects the Phase I primary endpoint and the protocol's specified toxicity-monitoring window.
|
|
Overall Response Rate (ORR)
時間枠：Beginning 1 month after the fourth dose (±7 days), then every 8 weeks for the first 12 months and every 12 weeks thereafter until disease progression or the end of study.
|
Proportion of participants achieving a complete response (CR) or partial response (PR), assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Participants who do not meet the criteria for an objective response will be considered non-responders. |
Beginning 1 month after the fourth dose (±7 days), then every 8 weeks for the first 12 months and every 12 weeks thereafter until disease progression or the end of study.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Participants With a ≥50% Reduction in CA-125
時間枠：From baseline to after 4 doses of VT-101 (Days 1, 8, 15, and 22).
|
Proportion of participants who achieve at least a 50% reduction in CA-125 levels relative to baseline. |
From baseline to after 4 doses of VT-101 (Days 1, 8, 15, and 22).
|
|
Progression-Free Survival (PFS)
時間枠：From treatment initiation until disease progression or death, with tumor imaging beginning 1 month after the fourth dose and then every 8 weeks for the first 12 months and every 12 weeks thereafter.
|
Time from treatment initiation to the first documented disease progression or death from any cause, whichever occurs first. Participants without documented progression or death will be censored at their last radiographic assessment for progression. |
From treatment initiation until disease progression or death, with tumor imaging beginning 1 month after the fourth dose and then every 8 weeks for the first 12 months and every 12 weeks thereafter.
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Michael Goodheart, MD、University of Iowa
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。